Zivo Bioscience, Inc. Common Stock
ZIVO
ZIVO was delisted on the 24th of November, 2023.
13 hedge funds and large institutions have $1.03M invested in Zivo Bioscience, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
8% more funds holding
Funds holding: 12 → 13 (+1)
12% less capital invested
Capital invested by funds: $1.17M → $1.03M (-$144K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$5.15K |
| 2 |
BlackRock
New York
|
+$3.81K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.26K |
| 4 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
+$279 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$35 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$15.6K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$1.22K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| 4 |
Morgan Stanley
New York
|
-$35 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $677K | -$15.6K | -895 | -2% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $250K | +$3.26K | +187 | +1% |
|
|
3
BlackRock
New York
| $37.8K | +$3.81K | +218 | +9% |
|
|
4
Wells Fargo
San Francisco,
California
| $28.3K | -$1.22K | -70 | -4% |
|
|
VCA
5
Verdence Capital Advisors
Hunt Valley,
Maryland
| $25K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $4.42K | +$5.15K | +295 | New |
|
|
BC
7
Bartlett & Co
Cincinnati,
Ohio
| $3K | – | – | – |
|
|
BCWM
8
Bartlett & Co Wealth Management
Cincinnati,
Ohio
| $2.5K | – | – | – |
|
9
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $1.57K | – | – | – |
|
|
10
Morgan Stanley
New York
| $313 | -$35 | -2 | -9% |
|
|
BAM
11
Belpointe Asset Management
Reno,
Nevada
| $238 | +$279 | +16 | New |
|
|
BCM
12
Bourgeon Capital Management
Darien,
Connecticut
| $78 | – | – | – |
|
|
13
Bank of America
Charlotte,
North Carolina
| $36 | +$35 | +2 | New |
|
|
TRCT
14
Tower Research Capital (TRC)
New York
| – | -$1K | -49 | Closed |
|
ZIVO Hedge Fund Activity: Q4 2022 in Review
13 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Zivo Bioscience, Inc. Common Stock (ZIVO) for Q4 2022, worth a combined $1.03M — down 12% from $1.17M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ZIVO positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $5.15K. The largest seller was Geode Capital Management, cutting an estimated $15.6K.
- 13 institutional investors held Zivo Bioscience, Inc. Common Stock (ZIVO) as of Q4 2022, up from 12 in Q3 2022.
- Funds reported $1.03M of Zivo Bioscience, Inc. Common Stock stock for Q4 2022, down 12% quarter-over-quarter.
- 3 funds opened new Zivo Bioscience, Inc. Common Stock positions in Q4 2022 and 2 closed out, a net change of +1 holder.
- The largest Zivo Bioscience, Inc. Common Stock buyer in Q4 2022 was UBS Group, an estimated $5.15K added.
- The largest Zivo Bioscience, Inc. Common Stock seller in Q4 2022 was Geode Capital Management, an estimated $15.6K sold.
Based on aggregated 13F filings for Q4 2022.